卵巢癌中顺铂/卡铂的交叉耐药性。
Cisplatin/carboplatin cross-resistance in ovarian cancer.
作者信息
Gore M E, Fryatt I, Wiltshaw E, Dawson T, Robinson B A, Calvert A H
机构信息
Gynaecology Unit, Royal Marsden Hospital, London, UK.
出版信息
Br J Cancer. 1989 Nov;60(5):767-9. doi: 10.1038/bjc.1989.356.
Abstract
Forty-six patients who were treated with cisplatin or carboplatin for ovarian cancer developed resistant disease (no change in measurable disease or progressive disease) and 'crossed over' to the other platinum compound. Three patients (6.5%) responded to this second treatment but these patients had no survival advantage compared to the non-responders. One responder had progressive disease on cisplatin before crossing over to carboplatin.
摘要
46例接受顺铂或卡铂治疗卵巢癌的患者出现耐药疾病（可测量疾病无变化或疾病进展）并“交叉”使用另一种铂类化合物。3例患者（6.5%）对第二次治疗有反应，但与无反应者相比，这些患者并无生存优势。1例有反应者在交叉使用卡铂之前使用顺铂时出现疾病进展。
相似文献
1
Cisplatin/carboplatin cross-resistance in ovarian cancer.卵巢癌中顺铂/卡铂的交叉耐药性。
Br J Cancer. 1989 Nov;60(5):767-9. doi: 10.1038/bjc.1989.356.
2
Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.
Gynecol Oncol. 1990 Feb;36(2):207-11. doi: 10.1016/0090-8258(90)90174-j.
3
Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study.
Eur J Cancer. 1991;27(2):135-8. doi: 10.1016/0277-5379(91)90470-x.
4
Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens.尽管之前接受过多种铂类方案治疗，但卵巢癌对顺铂/卡铂仍持续存在化疗敏感性。
Gynecol Oncol. 1997 Jun;65(3):434-6. doi: 10.1006/gyno.1997.4708.
5
A phase II trial of mitomycin in patients with epithelial ovarian carcinoma resistant to cisplatin or carboplatin.
Am J Clin Oncol. 1990 Oct;13(5):416-9. doi: 10.1097/00000421-199010000-00010.
6
Chemotherapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group.晚期卵巢癌的化疗。晚期卵巢癌试验组。
Cochrane Database Syst Rev. 2000(2):CD001418. doi: 10.1002/14651858.CD001418.
7
Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin.
J Natl Cancer Inst. 1989 Oct 4;81(19):1464-71. doi: 10.1093/jnci/81.19.1464.
8
Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.复发性卵巢癌患者对卡铂严重过敏反应后顺铂的安全性
Anticancer Res. 2003 Jul-Aug;23(4):3465-8.
9
High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease.在先前未经治疗且有残留病灶的卵巢癌患者中，采用卡铂和顺铂联合的大剂量铂类治疗。
J Clin Oncol. 1989 Oct;7(10):1469-73. doi: 10.1200/JCO.1989.7.10.1469.
10
Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy.
Gynecol Oncol. 2002 Mar;84(3):378-82. doi: 10.1006/gyno.2001.6519.
引用本文的文献
1
Resistance Management for Cancer: Lessons from Farmers.癌症耐药管理：从农民身上学到的经验。
Cancer Res. 2024 Nov 15;84(22):3715-3727. doi: 10.1158/0008-5472.CAN-23-3374.
2
Revisiting the Anti-Cancer Toxicity of Clinically Approved Platinating Derivatives.重新审视临床批准的铂类衍生物的抗癌毒性。
Int J Mol Sci. 2022 Dec 6;23(23):15410. doi: 10.3390/ijms232315410.
3
Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression.富含转移特性且 Twist 表达增加的卵巢癌细胞系中获得性顺铂耐药性的建立。
Int J Mol Sci. 2020 Oct 15;21(20):7613. doi: 10.3390/ijms21207613.
4
CRISPR/Cas9-mediated knockout of MLL5 enhances apoptotic effect of cisplatin in HeLa cells .CRISPR/Cas9介导的MLL5基因敲除增强顺铂对HeLa细胞的凋亡作用
EXCLI J. 2020 Jan 23;19:170-182. doi: 10.17179/excli2019-1957. eCollection 2020.
5
Structural insights into the promutagenic bypass of the major cisplatin-induced DNA lesion.结构洞察主要顺铂诱导的 DNA 损伤的促突变旁路。
Biochem J. 2020 Mar 13;477(5):937-951. doi: 10.1042/BCJ20190906.
6
Oxamusplatin: a cytotoxic Pt(ii) complex of a nitrogen mustard with resistance to thiol based sequestration displays enhanced selectivity towards cancer.奥沙铂：一种含氮芥的细胞毒性 Pt（ii）配合物，具有对基于巯基的隔离的抗性，对癌症具有更高的选择性。
Dalton Trans. 2020 Feb 25;49(8):2547-2558. doi: 10.1039/c9dt04269e.
7
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.一项 ipafricept（OMP54F28）联合紫杉醇和卡铂治疗复发性铂类敏感卵巢癌患者的 1b 期剂量递增研究。
Gynecol Oncol. 2019 Aug;154(2):294-301. doi: 10.1016/j.ygyno.2019.04.001. Epub 2019 Jun 4.
8
Structural basis for the bypass of the major oxaliplatin-DNA adducts by human DNA polymerase η.人源 DNA 聚合酶 η 绕过奥沙利铂-DNA 加合物的结构基础。
Biochem J. 2019 Feb 28;476(4):747-758. doi: 10.1042/BCJ20180848.
9
Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC.靶向癌症干细胞标志物醛脱氢酶1以克服非小细胞肺癌中的顺铂耐药性。
Oncotarget. 2017 Aug 3;8(42):72544-72563. doi: 10.18632/oncotarget.19881. eCollection 2017 Sep 22.
10
Tyrosine phosphorylation of HSC70 and its interaction with RFC mediates methotrexate resistance in murine L1210 leukemia cells.热休克蛋白70（HSC70）的酪氨酸磷酸化及其与复制因子C（RFC）的相互作用介导了小鼠L1210白血病细胞对甲氨蝶呤的耐药性。
Cancer Lett. 2015 Feb 1;357(1):231-241. doi: 10.1016/j.canlet.2014.11.036. Epub 2014 Nov 20.
本文引用的文献
1
Use of high dose cis-dichlorodiammine platinum (II) (NSC--119875) following failure on previous chemotherapy for advanced carcinoma of the ovary.
Br J Obstet Gynaecol. 1981 Dec;88(12):1192-9. doi: 10.1111/j.1471-0528.1981.tb01196.x.
2
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.顺-二氨-1,1-环丁烷二羧酸铂II的早期临床研究。
Cancer Chemother Pharmacol. 1982;9(3):140-7. doi: 10.1007/BF00257742.
3
Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.新型铂类类似物JM8用于晚期卵巢癌的II期研究。
Cancer Treat Rep. 1983 Nov;67(11):997-1000.
4
5
Ovarian trials at the Royal Marsden.
Cancer Treat Rev. 1985 Sep;12 Suppl A:67-71. doi: 10.1016/0305-7372(85)90020-9.
6
High-dose carboplatin in refractory ovarian cancer patients.
J Clin Oncol. 1987 Feb;5(2):197-201. doi: 10.1200/JCO.1987.5.2.197.
7
A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma.一项比较高剂量顺铂与低剂量顺铂及苯丁酸氮芥治疗晚期卵巢癌的前瞻性随机试验。
J Clin Oncol. 1986 May;4(5):722-9. doi: 10.1200/JCO.1986.4.5.722.
8
Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.抗癌铂类药物的细胞毒性机制：顺二氯二氨铂（II）和顺二氨（1,1-环丁烷二羧酸根）铂（II）仅在与DNA相互作用的动力学方面存在差异的证据。
Cancer Res. 1986 Apr;46(4 Pt 2):1972-9.
9
High-dose cisplatin in hypertonic saline in refractory ovarian cancer.高剂量顺铂联合高渗盐水治疗难治性卵巢癌
J Clin Oncol. 1985 Sep;3(9):1246-50. doi: 10.1200/JCO.1985.3.9.1246.
10
Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects.
Carcinogenesis. 1988 Jul;9(7):1283-7. doi: 10.1093/carcin/9.7.1283.
Zotero 插件